{"id":"https://openalex.org/W4396591121","doi":"https://doi.org/10.1158/1538-7445.sabcs23-po1-20-06","title":"Abstract PO1-20-06: Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 +/- pertuzumab in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan","display_name":"Abstract PO1-20-06: Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 +/- pertuzumab in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan","publication_year":2024,"publication_date":"2024-05-02","ids":{"openalex":"https://openalex.org/W4396591121","doi":"https://doi.org/10.1158/1538-7445.sabcs23-po1-20-06"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.sabcs23-po1-20-06","doi":"https://doi.org/10.1158/1538-7445.sabcs23-po1-20-06","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1158/1538-7445.sabcs23-po1-20-06","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5030502460","display_name":"Mark Daniel Pegram","orcid":"https://orcid.org/0000-0002-9743-8118","observed_orcids":["https://orcid.org/0000-0002-9743-8118"]},"institutions":[{"id":"https://openalex.org/I4210137306","display_name":"Stanford Medicine","ror":"https://ror.org/03mtd9a03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]},{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark Pegram","raw_affiliation_strings":["1Stanford School of Medicine;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Stanford School of Medicine;","institution_ids":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053172275","display_name":"Carmen Julia Calfa","orcid":"https://orcid.org/0000-0003-2824-0930","observed_orcids":["https://orcid.org/0000-0003-2824-0930"]},"institutions":[{"id":"https://openalex.org/I145608581","display_name":"University of Miami","ror":"https://ror.org/02dgjyy92","country_code":"US","type":"education","lineage":["https://openalex.org/I145608581"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Carmen Calfa","raw_affiliation_strings":["2University of Miami Miller School of Medicine;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2University of Miami Miller School of Medicine;","institution_ids":["https://openalex.org/I145608581"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Chris Chen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chris Chen","raw_affiliation_strings":["3Stanford University;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Stanford University;","institution_ids":["https://openalex.org/I97018004"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110475120","display_name":"Alfonso Cort\u00e9s Salgado","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210161852","display_name":"Hospital Universitario Ram\u00f3n y Cajal","ror":"https://ror.org/050eq1942","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210139293","https://openalex.org/I4210161852"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Alfonso Cortes Salgado","raw_affiliation_strings":["4Hospital Universitario Ramon y Cajal;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Hospital Universitario Ramon y Cajal;","institution_ids":["https://openalex.org/I4210161852"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089293098","display_name":"Arielle Lutterman Heeke","orcid":"https://orcid.org/0000-0001-7809-2564","observed_orcids":["https://orcid.org/0000-0001-7809-2564"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Arielle Heeke","raw_affiliation_strings":["5Levine Cancer Institute, Atrium Health;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Levine Cancer Institute, Atrium Health;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055664434","display_name":"Irene M. Kang","orcid":"https://orcid.org/0000-0002-9472-3853","observed_orcids":["https://orcid.org/0000-0002-9472-3853"]},"institutions":[{"id":"https://openalex.org/I4210110459","display_name":"City of Hope","ror":"https://ror.org/01z1vct10","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528","https://openalex.org/I4210110459"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Irene Kang","raw_affiliation_strings":["6City of Hope Orange County;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6City of Hope Orange County;","institution_ids":["https://openalex.org/I4210110459"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009030272","display_name":"Barbara Pistilli","orcid":"https://orcid.org/0000-0002-9184-7199","observed_orcids":["https://orcid.org/0000-0002-9184-7199"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Barbara Pistilli","raw_affiliation_strings":["7Gustave Roussy, France;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Gustave Roussy, France;","institution_ids":["https://openalex.org/I2801843802"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022876688","display_name":"Paula Raffin Pohlmann","orcid":"https://orcid.org/0000-0001-7914-5162","observed_orcids":["https://orcid.org/0000-0001-7914-5162"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paula Pohlmann","raw_affiliation_strings":["8The University of Texas MD Anderson Cancer Center;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"8The University of Texas MD Anderson Cancer Center;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090188675","display_name":"Hope S. Rugo","orcid":"https://orcid.org/0000-0001-6710-4814","observed_orcids":["https://orcid.org/0000-0001-6710-4814"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]},{"id":"https://openalex.org/I4210167126","display_name":"UCSF Helen Diller Family Comprehensive Cancer Center","ror":"https://ror.org/05yndxy10","country_code":"US","type":"facility","lineage":["https://openalex.org/I180670191","https://openalex.org/I4210110664","https://openalex.org/I4210167126"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hope Rugo","raw_affiliation_strings":["9Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"9Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States;","institution_ids":["https://openalex.org/I180670191","https://openalex.org/I4210167126"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082195410","display_name":"Cristina Saura","orcid":"https://orcid.org/0000-0001-8296-5065","observed_orcids":["https://orcid.org/0000-0001-8296-5065"]},"institutions":[{"id":"https://openalex.org/I4210127641","display_name":"Vall d'Hebron Hospital Universitari","ror":"https://ror.org/03ba28x55","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210127641","https://openalex.org/I4210153292"]},{"id":"https://openalex.org/I4387155398","display_name":"Vall d'Hebron Institute of Oncology","ror":"https://ror.org/054xx3904","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4387153040","https://openalex.org/I4387155398"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Cristina Saura","raw_affiliation_strings":["10Vall d\u2019Hebron Institute of Oncology (VHIO), Vall d\u2019Hebron University Hospital, Barcelona, Catalonia, Spain;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"10Vall d\u2019Hebron Institute of Oncology (VHIO), Vall d\u2019Hebron University Hospital, Barcelona, Catalonia, Spain;","institution_ids":["https://openalex.org/I4210127641","https://openalex.org/I4387155398"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072465879","display_name":"C\u00e9cile Vicier","orcid":"https://orcid.org/0009-0004-0671-2807","observed_orcids":["https://orcid.org/0009-0004-0671-2807"]},"institutions":[{"id":"https://openalex.org/I4210150365","display_name":"Institut Paoli-Calmettes","ror":"https://ror.org/04s3t1g37","country_code":"FR","type":"nonprofit","lineage":["https://openalex.org/I4210150365"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Cecile Vicier","raw_affiliation_strings":["11Institut Paoli-Calmette;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"11Institut Paoli-Calmette;","institution_ids":["https://openalex.org/I4210150365"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077599526","display_name":"Cecelia I. Pearson","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Cecelia I. Pearson","raw_affiliation_strings":["12Bolt Biotherapeutics;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"12Bolt Biotherapeutics;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103766483","display_name":"Coya Tapia","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Coya Tapia","raw_affiliation_strings":["13Bolt Biotherapeutics, Redwood City, California, United States;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"13Bolt Biotherapeutics, Redwood City, California, United States;","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Ming Yin","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ming Yin","raw_affiliation_strings":["12Bolt Biotherapeutics;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"12Bolt Biotherapeutics;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112689895","display_name":"Tai Yu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tai Yu","raw_affiliation_strings":["12Bolt Biotherapeutics;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"12Bolt Biotherapeutics;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066390728","display_name":"Michael N. Alonso","orcid":"https://orcid.org/0000-0003-3859-7669","observed_orcids":["https://orcid.org/0000-0003-3859-7669"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael N. Alonso","raw_affiliation_strings":["12Bolt Biotherapeutics;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"12Bolt Biotherapeutics;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065306642","display_name":"Edith A. Perez","orcid":"https://orcid.org/0000-0002-5037-6677","observed_orcids":["https://orcid.org/0000-0002-5037-6677","https://orcid.org/0000-0001-7009-7467"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Edith A. Perez","raw_affiliation_strings":["12Bolt Biotherapeutics;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"12Bolt Biotherapeutics;","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5012686198","display_name":"Joshua Z. Drago","orcid":"https://orcid.org/0000-0002-7245-1172","observed_orcids":["https://orcid.org/0000-0002-7245-1172"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joshua Drago","raw_affiliation_strings":["14Memorial Sloan Kettering Cancer Center, New York, New York, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"14Memorial Sloan Kettering Cancer Center, New York, New York, United States","institution_ids":["https://openalex.org/I1334819555"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":13,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"84","issue":"9_Supplement","first_page":"PO1","last_page":"20"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9916999936103821,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9916999936103821,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0019000000320374966,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0017999999690800905,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/integrated-sensing-and-communication","display_name":"integrated sensing and communication","score":0.6639999747276306},{"id":"https://openalex.org/keywords/her2-positive-metastatic-breast-cancer","display_name":"HER2-positive metastatic breast cancer","score":0.8410000205039978},{"id":"https://openalex.org/keywords/pertuzumab","display_name":"pertuzumab","score":0.843999981880188},{"id":"https://openalex.org/keywords/trastuzumab-deruxtecan","display_name":"trastuzumab deruxtecan","score":0.875},{"id":"https://openalex.org/keywords/tlr7-8-agonist","display_name":"TLR7/8 agonist","score":0.9160000085830688},{"id":"https://openalex.org/keywords/trastuzumab-biosimilar","display_name":"trastuzumab biosimilar","score":0.8420000076293945},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.5249999761581421},{"id":"https://openalex.org/keywords/innate-immune-activation","display_name":"innate immune activation","score":0.5170000195503235},{"id":"https://openalex.org/keywords/myeloid-activation","display_name":"myeloid activation","score":0.675000011920929},{"id":"https://openalex.org/keywords/her2-low","display_name":"HER2-low","score":0.38100001215934753}],"concepts":[{"id":"https://openalex.org/C2781164504","wikidata":"https://www.wikidata.org/wiki/Q1998021","display_name":"Pertuzumab","level":5,"score":0.9530825018882751},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6710353493690491},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.5237569808959961},{"id":"https://openalex.org/C197336794","wikidata":"https://www.wikidata.org/wiki/Q5161150","display_name":"Conjugate","level":2,"score":0.5116012692451477},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.49680688977241516},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.42925482988357544},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4164668321609497},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4141232669353485},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.3835687041282654},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3760223984718323},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.21093973517417908},{"id":"https://openalex.org/C33923547","wikidata":"https://www.wikidata.org/wiki/Q395","display_name":"Mathematics","level":0,"score":0.0},{"id":"https://openalex.org/C134306372","wikidata":"https://www.wikidata.org/wiki/Q7754","display_name":"Mathematical analysis","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.sabcs23-po1-20-06","doi":"https://doi.org/10.1158/1538-7445.sabcs23-po1-20-06","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1158/1538-7445.sabcs23-po1-20-06","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4399324382","https://openalex.org/W3129944833","https://openalex.org/W3178598370","https://openalex.org/W4388048230","https://openalex.org/W3103130214","https://openalex.org/W4200383558","https://openalex.org/W3170192471","https://openalex.org/W4387811519","https://openalex.org/W4379334613","https://openalex.org/W4388047785"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"Therapies":[2],"to":[3,39,59,87,310,376,402,457,465,481],"effectively":[4],"manage":[5],"patients":[6,282,575],"(pts)":[7],"with":[8,102,114,117,140,169,184,227,242,273,279,283,288,313,321,386,417,436,469,473,576,584],"metastatic":[9,578],"HER2+":[10,265],"breast":[11,243,579],"cancer":[12,580],"have":[13,344,350],"significantly":[14,130,172],"improved":[15,111],"over":[16],"the":[17,61,123,150,159,165,170,174,180,193,204,214,228,334,404,459,591],"years,":[18],"but":[19],"improvement":[20],"is":[21,30,57,307,401,479],"still":[22],"needed":[23],"in":[24,91,133,158,179,192,246,263,277,281,384,415,434,444,454,484,574],"both":[25],"efficacy":[26,132,425],"and":[27,65,81,94,127,176,223,233,267,276,349,373,414,428,433,448,453,463],"tolerability.":[28],"BDC-1001":[29,107,215,274,365,378,412,431,470,571],"an":[31],"ISAC":[32,153,171,229],"consisting":[33],"of":[34,106,125,147,152,167,207,213,231,237,249,333,357,411,430,461,563,590],"a":[35,40,48,67,92,103,234,247,259,268,380,391],"trastuzumab":[36,296,329,585],"biosimilar":[37],"conjugated":[38],"proprietary":[41],"cell":[42],"membrane":[43],"impermeable":[44],"TLR7/8":[45,566],"agonist":[46],"via":[47],"non-cleavable":[49],"linker,":[50],"administered":[51,364],"IV":[52],"every":[53,368],"2":[54,261,271,289,301,322,369,561],"weeks.":[55],"It":[56],"designed":[58],"trigger":[60],"innate":[62],"immune":[63,71],"system":[64],"generate":[66],"durable":[68,82],"tumor-targeted":[69],"adaptive":[70],"response.":[72],"Preclinical":[73],"studies":[74,101,197],"indicate":[75,110],"that":[76,199],"HER2-targeted":[77],"ISACs":[78],"elicit":[79],"potent":[80],"immune-mediated":[83],"antitumor":[84,238],"efficacy,":[85],"leading":[86],"complete":[88],"tumor":[89,136,181,445],"regression":[90],"TLR-":[93],"Fc":[95],"receptor-dependent":[96],"manner":[97],"[1].":[98,144],"Moreover,":[99,164],"preclinical":[100,121,196],"murine":[104],"surrogate":[105],"(trastuzumab-T785":[108],"ISAC)":[109],"anti-tumor":[112,156],"activity":[113,157,206,239,472],"trastuzumab-T785":[115,126],"compared":[116,183],"trastuzumab/pertuzumab.":[118],"In":[119],"these":[120],"studies,":[122],"combination":[124,166,201,278,385,416,435],"pertuzumab":[128,148,168,280,573],"demonstrated":[129,220],"enhanced":[131,189],"multiple":[134],"HER2-expressing":[135],"models,":[137],"including":[138,258,295,328],"those":[139],"lower":[141],"HER2":[142,161],"expression":[143],"The":[145,210,299,388,398],"addition":[146],"decreased":[149],"quantity":[151],"required":[154],"for":[155],"JIMT-1":[160],"IHC2+":[162],"model.":[163],"increased":[173],"cytokine":[175],"chemokine":[177],"concentrations":[178],"xenografts,":[182],"monotherapy":[185],"or":[186,290,323,342,359,383,474,496],"trastuzumab/pertuzumab,":[187],"indicating":[188],"myeloid":[190],"activation":[191],"tumor.":[194],"These":[195],"suggest":[198],"this":[200],"may":[202],"enhance":[203],"clinical":[205],"trastuzumab-based":[208],"ISACs.":[209],"completed":[211],"part":[212],"dose":[216],"escalation":[217],"trial":[218,262,272,389],"(NCT04278144)":[219],"safety,":[221,423],"PK":[222],"pharmacodynamic":[224,442],"changes":[225],"compatible":[226],"mechanism":[230,460],"action,":[232],"wide":[235],"range":[236],"(incl.":[240],"cases":[241],"cancer);":[244],"resulting":[245],"RP2D":[248],"20":[250,366],"mg/kg":[251,367],"q2w":[252],"[2].":[253],"Two":[254],"trials":[255],"are":[256],"underway,":[257],"Phase":[260,270,300,560],"other":[264],"malignancies,":[266],"randomized":[269,304,374],"alone":[275,413,432],"HER2-positive":[284,314,577],"MBC":[285,318],"previously":[286,319,582],"treated":[287,320,583],"more":[291,324],"prior":[292,325,335],"anti-HER2":[293,326],"therapies,":[294,327],"deruxtecan.":[297],"Methods:":[298],"multicenter,":[302],"open-label,":[303],"study":[305,478,562],"(BBI-20231001)":[306],"enrolling":[308],"up":[309],"66":[311],"pts":[312],"(ASCO/CAP":[315],"guidelines":[316],"2018)":[317],"deruxtecan":[330,586],"as":[331,379],"one":[332],"therapies.":[336],"Pts":[337,361],"must":[338],"be":[339,363],"18":[340],"years":[341],"older,":[343],"measurable":[345],"disease":[346],"(RECIST":[347],"v1.1),":[348],"Eastern":[351],"Cooperative":[352],"Oncology":[353],"Group":[354],"performance":[355],"status":[356],"0":[358],"1.":[360,499],"will":[362,421,440],"weeks":[370],"(IV":[371],"q2w)":[372],"1:1":[375],"receive":[377],"single":[381],"agent":[382],"pertuzumab.":[387,418,437,476],"has":[390],"Simon":[392],"2-stage":[393],"design":[394],"within":[395],"each":[396],"arm.":[397],"primary":[399],"objective":[400],"determine":[403],"overall":[405],"response":[406],"rate":[407],"per":[408],"RECIST":[409],"v1.1":[410],"Secondary":[419],"objectives":[420,439],"evaluate":[422],"additional":[424,488],"parameters,":[426],"pharmacokinetics,":[427],"immunogenicity":[429],"Exploratory":[438],"include":[441],"biomarkers":[443,467],"tissue":[446],"(baseline":[447],"on-treatment":[449],"biopsies":[450],"if":[451],"feasible)":[452],"peripheral":[455],"blood":[456],"elucidate":[458],"action":[462],"seek":[464],"identify":[466],"associated":[468],"biological":[471],"without":[475],"This":[477],"expected":[480],"initiate":[482],"accrual":[483],"2H":[485],"2023.":[486],"For":[487],"information,":[489],"please":[490],"contact":[491],"Bolt":[492],"Biotherapeutics":[493],"at":[494],"1-650-665-9295":[495],"info@boltbio.com.":[497],"References":[498],"S.":[500],"Ackerman":[501],"et.":[502,510],"al.,":[503],"Nature":[504],"Cancer,":[505],"2021":[506],"2.":[507],"Li,":[508],"B.T.":[509],"al.":[511],"J":[512],"Clin":[513],"Oncol,":[514],"2023":[515,592,598],"(abstr":[516],"2538)":[517],"Citation":[518],"Format:":[519],"Mark":[520],"Pegram,":[521],"Carmen":[522],"Calfa,":[523],"Chris":[524],"Chen,":[525],"Alfonso":[526],"Cortes":[527],"Salgado,":[528],"Arielle":[529],"Heeke,":[530],"Irene":[531],"Kang,":[532],"Barbara":[533],"Pistilli,":[534],"Paula":[535],"Pohlmann,":[536],"Hope":[537],"Rugo,":[538],"Cristina":[539],"Saura,":[540],"Cecile":[541],"Vicier,":[542],"Cecelia":[543],"I.":[544],"Pearson,":[545],"Coya":[546],"Tapia,":[547],"Ming":[548],"Yin,":[549],"Tai":[550],"Yu,":[551],"Michael":[552],"N.":[553],"Alonso,":[554],"Edith":[555],"A.":[556],"Perez,":[557],"Joshua":[558],"Drago.":[559],"novel":[564],"HER2-targeting,":[565],"immune-stimulating":[567],"antibody":[568],"conjugate":[569],"(ISAC)":[570],"+/-":[572],"(MBC)":[581],"[abstract].":[587],"In:":[588],"Proceedings":[589],"San":[593,601],"Antonio":[594],"Breast":[595],"Cancer":[596,607],"Symposium;":[597],"Dec":[599],"5-9;":[600],"Antonio,":[602],"TX.":[603],"Philadelphia":[604],"(PA):":[605],"AACR;":[606],"Res":[608],"2024;84(9":[609],"Suppl):Abstract":[610],"nr":[611],"PO1-20-06.":[612]},"counts_by_year":[],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2024-05-03T00:00:00"}